A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin‐associated iron overload diseases
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Summary: Ferroportin‐related iron overload disease differs from haemochromatosis in that it has a dominant mode of inheritance and is usually associated with macrophage iron sequestration. However, it is thought that mutations with opposite effects on protein functions, i.e. loss‐of‐function versus gain‐of‐function mutations, are responsible for variable phenotype presentations. The present study investigated the functional relevance of a novel ferroportin variant: the c.1502 A>G transition, which changes amino acid 501 from tyrosine to cysteine (p.Y501C). This novel variant was identified in a pedigree originating from Central Italy and, although an intra‐familial phenotype heterogeneity was observed, it co‐segregated with an iron overload picture similar to that of the HFE‐related typical haemochromatosis. In cultured cells, the p.Y501C mutant protein reached the plasma membrane and retained a full iron export ability. By contrast, it was resistant to inhibition by hepcidin. These findings confirm that certain ferroportin mutations compromise the activity of hepcidin in iron homeostasis, mimicking hepcidin deficiency as described in all types of hemochromatosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hereditary Hemochromatosis — A New Look at an Old Disease
Pietrangelo, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031573 · Cited by 992 · cited 2×
“Additionally, these rarer HC forms are inherited as recessive traits (Pietrangelo, 2004; Le Gac & Férec, 2005).”
BackgroundThe Molecular Mechanism of Hepcidin-mediated Ferroportin Down-Regulation
De Domenico, I., Ward, D. M., Langelier, C., Vaughn, M. B., Nemeth, E., Sundquist, W. I., Ganz, T., Musci, G., & Kaplan, J. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-01-0060 · Cited by 434
Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin
Drakesmith, H., Schimanski, L. M., Ormerod, E., Merryweather-Clarke, A. T., Viprakasit, V., Edwards, J. P., Sweetland, E., Bastin, J. M., Cowley, D., Chinthammitr, Y., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0561 · Cited by 264 · cited 3×
“Another point of interest is that certain ferroportin mutants have been proved to show different degrees of resistance to hepcidin (Drakesmith et al, 2005; Rice et al, 2009).”
BackgroundMethodThe molecular basis of ferroportin-linked hemochromatosis
De Domenico, I., Ward, D. M., Nemeth, E., Vaughn, M. B., Musci, G., Ganz, T., & Kaplan, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503804102 · Cited by 230 · cited 1×
“…ferroportin mutants that retain a full iron export capability but are insensitive to downregulation by hepcidin (i.e. gain-of-function mutants) has been demonstrated by several studies (De Domenico et al, 2005; Drakesmith et al, 2005; Wallace et al, 2007; Fernandes et al, 2009; Rice et al, 2009).”
BackgroundHemochromatosis: An endocrine liver disease
Pietrangelo, A. (2007) · Hepatology · doi:10.1002/hep.21886 · Cited by 212 · cited 1×
“Thus, it corresponds to an iron overload syndrome that is clearly distinctive from HC types 1–3, and which is best recognized as the ferroportin disease (Pietrangelo, 2007).”
BackgroundIn vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations
Schimanski, L. M., Drakesmith, H., Merryweather-Clarke, A. T., Viprakasit, V., Edwards, J. P., Sweetland, E., Bastin, J. M., Cowley, D., Chinthammitr, Y., Robson, K. J. H., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4502 · Cited by 212
Sham, R. L., Phatak, P. D., West, C., Lee, P., Andrews, C., & Beutler, E. (2005) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2004.12.002 · Cited by 146
Wallace, D. F., Clark, R. M., Harley, H. A. J., & Subramaniam, V. N. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2003.12.008 · Cited by 83
Research works printed but not linked: 18
- Adams P., 2000, EASL International Consensus Conference on hemochromatosis, Journal of Hepatology, 33, 485, 10.1016/S0168-8278(01)80874-6 · DOI · Paper page
- 10.1007/s10534-006-9030-2 · DOI
- 10.1136/gut.52.8.1215 · DOI · Paper page
- De Domenico I., 2006, Iron overload due to mutations in ferroportin, Haematologica, 91, 92
- 10.1016/j.cmet.2008.07.002 · DOI · Paper page
- 10.1073/pnas.0900453106 · DOI · Paper page
- 10.1182/blood-2008-03-146134 · DOI · Paper page
- 10.1007/s00439-005-1307-y · DOI
- 10.1038/sj.ejhg.5201490 · DOI
- 10.1016/j.bcmd.2005.04.005 · DOI
- 10.1126/science.1104742 · DOI · Paper page
- 10.1038/90038 · DOI · Paper page
- 10.1111/j.1399-0004.2007.00950.x · DOI · Paper page
- 10.1056/NEJM199909023411003 · DOI · Paper page
- 10.1016/j.jmb.2008.12.063 · DOI · Paper page
- Rivard S.R., 2003, Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a newmissense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French‐Canadian family, Haematologica, 88, 824
- 10.1016/j.beha.2004.08.023 · DOI
- 10.1016/j.jhep.2007.01.033 · DOI
Cited by
Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms
Billesbølle, C. B., Azumaya, C. M., Kretsch, R. C., Powers, A. S., Gonen, S., Schneider, S., Arvedson, T., Dror, R. O., Cheng, Y., & Manglik, A. (2020) · Nature · doi:10.1038/s41586-020-2668-z · Cited by 344
Aschemeyer, S., Qiao, B., Stefanova, D., Valore, E. V., Sek, A. C., Ruwe, T. A., Vieth, K. R., Jung, G., Casu, C., Rivella, S., et al. (2018) · Blood · doi:10.1182/blood-2017-05-786590 · Cited by 325
Review article: the iron overload syndromes
Siddique, A., & Kowdley, K. V. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05051.x · Cited by 162
Ferroportin disease: pathogenesis, diagnosis and treatment
Pietrangelo, A. (2017) · Haematologica · doi:10.3324/haematol.2017.170720 · Cited by 151
Ferroportin disease: a systematic meta-analysis of clinical and molecular findings
Mayr, R., Janecke, A. R., Schranz, M., Griffiths, W. J. H., Vogel, W., Pietrangelo, A., & Zoller, H. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.016 · Cited by 133
“Ferroportin disease is genetically heterogeneous with 36 different SLC40A1 mutations reported [8–10,12,26–29,38–41,45–68] as summarized in Table 3.”
Background
Metadata
- Authors
- Létocart, E., Le Gac, G., Majore, S., Ka, C., Radio, F. C., Gourlaouen, I., De Bernardo, C., Férec, C., & Grammatico, P.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2009-10-12
- Volume
- 147
- Issue
- 3
- Pages
- 379-385
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1963877188
- Cited by
- 46
- References
- 8
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin‐associated iron overload diseases. https://app.cochat.ai/papers/10.1111/j.1365-2141.2009.07834.x
- The paper
- Létocart, E., Le Gac, G., Majore, S., Ka, C., Radio, F. C., Gourlaouen, I., De Bernardo, C., Férec, C., & Grammatico, P. (2009). A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin‐associated iron overload diseases. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2009.07834.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.